Inflammation and Arterial Hypertension: From Pathophysiological Links to Risk Prediction

E-ISSN： 1875-533x|22|23|2754-2761

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.22, Iss.23, 2015-01, pp. : 2754-2761

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of Redox Homeostasis and Inflammation in the Pathogenesis of Pulmonary Arterial Hypertension

Current Medicinal Chemistry, Vol. 25, Iss. 11, 2018-04 ,pp. : 1340-1351

Bentham Science Publishers

Access to resources Recommend Favorite

Dasatinib [Sprycel] may increase the risk of pulmonary arterial hypertension (PAH)

Reactions Weekly, Vol. 1, Iss. 1374, 2011-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence

By Provencher Steeve Sitbon Olivier Simonneau Gérald

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 8, 2005-07 ,pp. : 1337-1348

Informa Healthcare

Access to resources Recommend Favorite

Editorial [Hot Topic: Cardiovascular Risk and Inflammation: Pathophysiological Mechanisms, Drug Design, and Targets Executive (Guest Editor: Armen Yuri Gasparyan)]

Current Pharmaceutical Design, Vol. 18, Iss. 11, 2012-04 ,pp. : 1447-1449

Bentham Science Publishers

Access to resources Recommend Favorite

Tadalafil: In Pulmonary Arterial Hypertension

By Croxtall Jamie D. Lyseng-Williamson Katherine A.

Drugs, Vol. 70, Iss. 4, 2010-03 ,pp. : 479-488

Adis International

Access to resources Recommend Favorite